Furthermore, given that genetic mutations can induce certain gene expression phenotypes in CRC, a comprehensive phenotypic exploration (including not only cancer epithelial cells, but also the tumor cell-type microenvironment) is critically required to establish biomarkers that can robustly predict the response to anti-EGFR therapies. This evidence concerns the gene EGFR and cancer.